INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a
- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use
Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy Precision will receive $100 million cash upfront and an equity investment by Lilly of $35
- ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment - Authorization enables use of baricitinib in combination with remdesivir in hospitalized patients needing oxygen INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and
BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.
- In new results published in The Lancet Diabetes & Endocrinology, Jardiance reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established
INDIANAPOLIS , Nov. 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual fireside
INDIANAPOLIS , Nov. 12, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020 . Andrew Adams , Ph.D., vice president of new therapeutic modalities and scientific leader for Lilly 's anti-COVID-19
Webcast will not include results from any Phase 3 clinical trials INDIANAPOLIS , Nov. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in
- Bamlanivimab is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients - U.S. government will allocate 300,000 doses of bamlanivimab to high-risk patients, with no out-of-pocket costs for the medication INDIANAPOLIS , Nov.